Literature DB >> 11929053

A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria.

E I Minder1, L Gouya, X Schneider-Yin, J C Deybach.   

Abstract

Erythropoietic protoporphyria (EPP), an inborn error of heme metabolism, causes in the majority of the patients only a symptom of photosensitivity. However, around 2% of the EPP sufferers develop liver complication in the form of liver cirrhosis and progressive liver failure. Mutations in the human ferrochelatase (FECH) gene causing EPP are highly heterogeneous and mostly family-specific. Actually, 62 FECH mutations have been published, 48 of them are "null allele" mutations inducing the formation of a truncated protein. The remaining 14 are missense mutations. In contrast to the null allele mutations, the latter lead to substitution of a single amino acid residue in the protein molecule and generate an enzyme that, although functionally impaired, is in its full length. In order to study the association between "null allele" mutation and liver complication, we combined our data with those in the literature. A total of 112 EPP patients were counted among 93 EPP families with a known FECH mutation. All 18 EPP patients who had severe liver complication carried a "null allele" mutation. In contrast, none of the 20 patients who carried a missense mutation had developed liver complication till the time of study (Fisher's exact test, p<0.05). High protoporphyrin blood concentration are considered to be a sign of an increased risk of liver disease. No correlation of protoporphyrin blood level with the type of mutation, was found, if patients with overt liver disease were excluded from the sample. Furthermore, no significant association of the liver complication with the location of the mutation within the FECH gene was found (Fisher exact test p = 0.46). These available data indicate a significant genotype-phenotype correlation between "null allele" mutation and protoporphyrin related liver disease in EPP. Although the risk for a EPP patient with a missense mutation to develop liver disease cannot be totally eliminated based on these data, it is comparably low.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929053

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  10 in total

Review 1.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

Review 2.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 3.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

4.  Exacerbation of erythropoietic protoporphyria by hyperthyroidism.

Authors:  Elisabeth I Minder; Andreas R Haldemann; Xiaoye Schneider-Yin
Journal:  J Inherit Metab Dis       Date:  2010-11-11       Impact factor: 4.982

Review 5.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

6.  Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria.

Authors:  Victoria E Parera; Rita H Koole; Gardi Minderman; Annie Edixhoven; Maria V Rossetti; Alcira Batlle; Felix W M de Rooij
Journal:  Mol Med       Date:  2009-08-12       Impact factor: 6.354

Review 7.  Liver transplantation in the management of porphyria.

Authors:  Ashwani K Singal; Charles Parker; Christine Bowden; Manish Thapar; Lawrence Liu; Brendan M McGuire
Journal:  Hepatology       Date:  2014-07-29       Impact factor: 17.425

Review 8.  The porphyrias: advances in diagnosis and treatment.

Authors:  Manisha Balwani; Robert J Desnick
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

9.  Delayed photosensitivity in a child with erythropoietic protoporphyria : a case report.

Authors:  James Kiberd; Laura Finlayson
Journal:  SAGE Open Med Case Rep       Date:  2018-05-23

Review 10.  Erythropoietic protoporphyria.

Authors:  Mario Lecha; Hervé Puy; Jean-Charles Deybach
Journal:  Orphanet J Rare Dis       Date:  2009-09-10       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.